OVERSEA CHINESE BANKING Corp Ltd Takes $1.92 Million Position in IQVIA Holdings Inc. $IQV

OVERSEA CHINESE BANKING Corp Ltd bought a new position in IQVIA Holdings Inc. (NYSE:IQV) during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 10,096 shares of the medical research company’s stock, valued at approximately $1,917,000.

A number of other hedge funds have also added to or reduced their stakes in the stock. Alliancebernstein L.P. raised its stake in shares of IQVIA by 0.6% in the second quarter. Alliancebernstein L.P. now owns 3,555,929 shares of the medical research company’s stock worth $560,379,000 after purchasing an additional 19,573 shares during the last quarter. Artisan Partners Limited Partnership bought a new stake in IQVIA during the second quarter worth $515,772,000. JPMorgan Chase & Co. raised its position in IQVIA by 22.8% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,126,171 shares of the medical research company’s stock valued at $492,659,000 after buying an additional 581,157 shares during the last quarter. Nordea Investment Management AB lifted its stake in IQVIA by 12.3% during the 3rd quarter. Nordea Investment Management AB now owns 2,314,219 shares of the medical research company’s stock valued at $421,257,000 after acquiring an additional 253,759 shares in the last quarter. Finally, Lazard Asset Management LLC boosted its holdings in IQVIA by 6.1% during the 2nd quarter. Lazard Asset Management LLC now owns 1,866,537 shares of the medical research company’s stock worth $294,145,000 after acquiring an additional 107,500 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

Analyst Ratings Changes

IQV has been the topic of a number of recent analyst reports. HSBC raised shares of IQVIA from a “hold” rating to a “buy” rating and raised their price target for the company from $195.00 to $235.00 in a research report on Thursday, October 9th. UBS Group lifted their target price on shares of IQVIA from $250.00 to $280.00 and gave the stock a “buy” rating in a research report on Thursday, January 8th. Stifel Nicolaus upped their target price on IQVIA from $234.00 to $254.00 and gave the company a “buy” rating in a report on Wednesday, October 29th. Evercore ISI lifted their price target on IQVIA from $220.00 to $240.00 and gave the stock an “outperform” rating in a report on Wednesday, October 8th. Finally, BMO Capital Markets assumed coverage on IQVIA in a research report on Thursday, November 13th. They issued an “outperform” rating and a $260.00 price objective on the stock. Two research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, IQVIA currently has an average rating of “Moderate Buy” and a consensus price target of $249.19.

Insider Buying and Selling at IQVIA

In other news, insider Eric Sherbet sold 4,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total value of $878,800.00. Following the sale, the insider owned 27,108 shares of the company’s stock, valued at $5,955,627.60. The trade was a 12.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 1.60% of the stock is owned by insiders.

IQVIA Price Performance

Shares of NYSE IQV opened at $241.38 on Friday. The company has a current ratio of 0.70, a quick ratio of 0.70 and a debt-to-equity ratio of 2.03. The stock has a fifty day simple moving average of $226.75 and a two-hundred day simple moving average of $202.50. IQVIA Holdings Inc. has a 1-year low of $134.65 and a 1-year high of $247.04. The firm has a market cap of $41.11 billion, a price-to-earnings ratio of 33.11, a price-to-earnings-growth ratio of 2.46 and a beta of 1.36.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Tuesday, October 28th. The medical research company reported $3.00 EPS for the quarter, beating analysts’ consensus estimates of $2.98 by $0.02. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The firm had revenue of $4.10 billion for the quarter, compared to analysts’ expectations of $4.07 billion. During the same quarter in the prior year, the firm earned $2.84 EPS. The business’s revenue for the quarter was up 5.2% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. Analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.